|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/5/2012 7:25:42 AM
US-based drug firm Eli Lilly and Co and domestic firm Strides ArcolabBSE -3.27 % today said they have entered into a pact to expand marketing of generic cancer medicines in the emerging markets. As a part of the arrangement, Eli Lilly will in-licence a portfolio of branded generic injectible and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, the companies said in a joint statement. Agila Specialties will manufacture the cancer medicines, and Lilly will register and market them in geographies across the emerging markets, it added. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high- quality branded generic oncology products to the portfolio in the future, the statement said. The two companies, however, did not disclose the financial details of the agreement. Commenting on the development, Lilly Senior Vice- President and President of its emerging markets division Jacques Tapiero said: "Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets".
|
|
|
|
|
|
|
|
|
|
|